Polaryx Therapeutics announces it has selected a contract research organization for its SOTERIA Phase 2 basket trial of lead candidate PLX-200 across four lysosomal storage disorders, reiterating plans to initiate the study in the first half of 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.